Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
Date:8/11/2008

CAMBRIDGE, Mass., Aug. 11 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that the first patient has received an initial dose in a Phase 1 clinical study of the Company's first oncology product, MM-121, a fully human monoclonal antibody and a first-in-class therapeutic designed to block signaling of the ErbB3 receptor.

ErbB3 is a receptor in the ErbB family, a pathway that plays a critical role in cancer signaling. With the initiation of the Phase 1 trial, MM-121 becomes the first systems biology product as well as the first selective ErbB3 antagonist to enter human clinical development.

"We used a combination of high-throughput biology and computer simulation to discern the importance of targeting ErbB3 signaling in tumor cells," said Dr. Ulrik B. Nielsen, Senior Vice President of Research. "We believe this is the first systems-designed therapeutic in clinical development. Until now, computer simulation has not been widely applied toward understanding optimal therapeutic strategies for treating cancers driven by complex signaling pathways."

Preclinical data demonstrating the impact of MM-121 in multiple cancer models were presented at the annual meeting of the American Association for Cancer Research in April. The Phase 1 dose escalation study will evaluate the safety and pharmacokinetics (PK) of MM-121. Enrollment is underway at Fox Chase Cancer Center and two additional leading oncology sites are expected to participate in the trial later this year.

"ErbB3 is now recognized as a potentially important target in many types of cancer including lung, breast, colorectal, ovarian and others," said Dr. William J. Slichenmyer, Senior Vice President and Chief Medical Officer at Merrimack. "Preclinical studies of MM-121 have demonstrated antitumor activity in a wide range of tumor types and a very favorable safety profile. We are optimistic that these findings may translate into clinical benefit for patients who participat
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
2. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2015)... -- Current asthma medications, which work by suppressing ... the airways, can stop working over time. A ... Hospital and Harvard Medical School supports a surprising ... nerve endings in the lungs that help drive ... journal Neuron on June 25, the ...
(Date:6/25/2015)... (PRWEB) , ... June 25, 2015 , ... ... Framingham State University will enjoy (8) new chemistry laboratories, each exclusively using filtered ... week, Erlab’s team finished installing the (49) filtered fume hoods needed for their ...
(Date:6/25/2015)... , June 25, 2015  The Galien Awards Committee ... Genome Sciences and Medical Genetics at the University of ... Bono Humanum Award at the ninth annual Prix Galien ...   The Pro Bono Humanum Award recognizes ... the first woman recipient of the award.   ...
(Date:6/25/2015)... June 25, 2015 iAngels ... with Startup Nation,s leading angels and gain access to ... Darya Fuks as Portfolio Manager.  , ,Fuks, a ... lead iAngels, deal flow and due diligence activities for ... all iAngels portfolio companies. An investment banker with deep ...
Breaking Biology Technology:Targeting Nerve Endings To Curb Allergic Asthma 2Targeting Nerve Endings To Curb Allergic Asthma 3Targeting Nerve Endings To Curb Allergic Asthma 4Targeting Nerve Endings To Curb Allergic Asthma 5This Summer Erlab Completes the Largest Installation of Filtered Fume Hoods in the World 2The Prix Galien USA Awards Committee Selects Professor Mary-Claire King as 2015 Pro Bono Humanum Honoree 2The Prix Galien USA Awards Committee Selects Professor Mary-Claire King as 2015 Pro Bono Humanum Honoree 3Former J.P. Morgan Vice President Darya Fuks Joins iAngels 2Former J.P. Morgan Vice President Darya Fuks Joins iAngels 3
... 11 CV Therapeutics,Inc. (Nasdaq: CVTX ) today ... 2007 after the market closes on Tuesday, November 6,2007. ... p.m. EST,1:30 p.m. PST, on the company,s website. ... the Company,s website at, http://www.cvt.com and go to ...
... - The Board of,Directors of Immunotec Inc. is ... A. Northrop as President and Chief Executive Officer, ... Board of Directors of Immunotec Inc., Mr. Northrop ... success in rapid growth,situations, Mr. Northrop has impressive ...
... an Eden Prairie-,based molecular diagnostics service and technology company, ... its CFO, and Elizabeth A. Skinner,as VP - Legal, ... of Edwin Watts Golf, and has previously,served as VP ... Allied Signal,Aerospace, and corporate controller of NCR Corporation. He ...
Cached Biology Technology:CV Therapeutics To Announce 2007 Third Quarter Financial Results on Tuesday, November 6, 2007 2Immunotec Inc. announces appointment of President & CEO James A. Northrop 2Access Genetics Announces New Executive Appointments 2
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... touch fingerprint sensors in the company,s portfolio from one of ... are planned to mainly take place during the third quarter ... Asia . Jörgen Lantto, CEO ... of    the   growing interest from smartphone OEMs in ...
(Date:6/15/2015)... YORK , June 15, 2015 ... today from Telstra reveals the majority of US consumers using ... them via biometrics, such as fingerprint and voiceprint, instead of ... According to Telstra,s " Mobile Identity   - ... " report, with smartphones now the primary channel used ...
(Date:6/11/2015)... 11, 2015 Daon, a global leader ... its IdentityX Mobile Authentication Platform v4.0 has been ... is an industry consortium launched in 2013 to ... stronger authentication.  In order to receive certification, a ... series of tests that measure compliance and ensure ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... Group, Inc. (OTC Bulletin Board: MDXG ), ... biomaterial-based products, announced today that its results for the ... and Company guidance will be released after the closing ... timing of the earnings announcement allows MiMedx time to ...
... the oocysts from the Cryptosporidium genus and cysts ... greatest public health problems in water supply, because these parasites ... Hermida, a scientist at the Galician Institute for Food Quality ... A team led by this researcher took 232 water samples ...
... at IRB Barcelona have completed the 3D structural sequence ... substances between the extra and intracellular milieu. This finding ... occur in these relevant proteins during basic cell processes, ... cell volume, and nerve transmission. The exchange ...
Cached Biology News:MiMedx Group, Inc. Announces Release Date for 2010 Fourth Quarter and Full Year Results 2Parasitic protozoons survive waste water and drinking water treatment plants in Galicia 2Researchers achieve a full film frame of a family of proteins essential for cell function 2
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... for relax positively and negatively supercoiled DNA in ... , Studying the effects of supercoiling on transcription ... vitro , Determining the degree of supercoiling ... plasmids that differ in length by only one ...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
Biology Products: